PROTEOSTASIS THERAPEUTICS IN's ticker is PTI and the CUSIP is 74373B109. A total of 42 filers reported holding PROTEOSTASIS THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $45,000 | -19.6% | 41,200 | 0.0% | 0.00% | – |
| Q2 2020 | $56,000 | +19.1% | 41,200 | 0.0% | 0.00% | – |
| Q1 2020 | $47,000 | -50.0% | 41,200 | 0.0% | 0.00% | – |
| Q4 2019 | $94,000 | +168.6% | 41,200 | 0.0% | 0.00% | – |
| Q3 2019 | $35,000 | -12.5% | 41,200 | 0.0% | 0.00% | – |
| Q2 2019 | $40,000 | -23.1% | 41,200 | 0.0% | 0.00% | – |
| Q1 2019 | $52,000 | -60.9% | 41,200 | 0.0% | 0.00% | – |
| Q4 2018 | $133,000 | +34.3% | 41,200 | 0.0% | 0.00% | – |
| Q3 2018 | $99,000 | -13.9% | 41,200 | 0.0% | 0.00% | – |
| Q2 2018 | $115,000 | -41.3% | 41,200 | 0.0% | 0.00% | – |
| Q1 2018 | $196,000 | -18.3% | 41,200 | 0.0% | 0.00% | – |
| Q4 2017 | $240,000 | +175.9% | 41,200 | 0.0% | 0.00% | – |
| Q3 2017 | $87,000 | -54.9% | 41,200 | 0.0% | 0.00% | – |
| Q2 2017 | $193,000 | -40.1% | 41,200 | 0.0% | 0.00% | -100.0% |
| Q1 2017 | $322,000 | -36.2% | 41,200 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $505,000 | – | 41,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 3,804,027 | $17,803,000 | 2.95% |
| HARBOURVEST PARTNERS LLC | 440,627 | $2,062,000 | 0.89% |
| NEA Management Company, LLC | 3,556,778 | $16,646,000 | 0.61% |
| Rock Springs Capital Management LP | 450,000 | $2,106,000 | 0.11% |
| Bain Capital Public Equity Management, LLC | 263,498 | $1,233,000 | 0.07% |
| ELEMENT CAPITAL MANAGEMENT LLC | 65,973 | $309,000 | 0.06% |
| Hillhouse Capital Management | 865,923 | $4,053,000 | 0.06% |
| SABBY MANAGEMENT, LLC | 125,151 | $586,000 | 0.04% |
| Marshall Wace North America L.P. | 684,124 | $3,421,000 | 0.02% |
| FNY Partners Fund LP | 20,127 | $94,000 | 0.02% |